FOLD Amicus Therapeutics Inc.

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025.

Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at . Web participants are encouraged to register on the website 15 minutes prior to the start of the call.

An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at , and follow on and .

CONTACT:

Investors:

Amicus Therapeutics

Andrew Faughnan

Vice President, Investor Relations



(609) 662-3809

Media:

Amicus Therapeutics

Diana Moore

Head of Global Corporate Affairs and Communications



(609) 662-5079

FOLD–G



EN
21/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amicus Therapeutics Inc.

 PRESS RELEASE

Amicus Therapeutics Announces First Quarter 2025 Financial Results and...

Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates 1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER Reiterating GAAP Profitability During H2 2025 Conference Call and We...

 PRESS RELEASE

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement f...

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies Dimerix successfully completed Type C meeting with the FDA in March 2025, aligning on proteinuria as the primary endpoint for approval Dimerix to receive US$30 million (~AU$48 million) upfront payment, up to US$560 million (~AU$892 million) for success-ba...

 PRESS RELEASE

Amicus Therapeutics to Announce First Quarter 2025 Financial Results o...

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A ...

 PRESS RELEASE

Amicus Therapeutics to Present at Upcoming Investor Conferences in Mar...

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. TD Cowen 45th Annual Health Care Conference in Boston, MA, on Tuesday, March 4, 2025, at 9:50 a.m. ETLeerink Partners 2025 Global Healthcare Conference in Miami, FL, on Monday, March 10, 2025, at 10:00 a.m. ET A live audio webcast of each presentation can also be accessed via the investors section of the ...

 PRESS RELEASE

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Cor...

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates 2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2024. “We clo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch